Profiling How Nanoparticles Interact with Blood for Safer Therapies
Official title: Profiling LNP and Blood Elements Interactions
Funded at University of New Haven · NIH-11444679 · Data updated 2026-11-12
This project studies how lipid-based nanoparticles interact with blood components to improve the safety and effectiveness of targeted drug delivery.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of New Haven NIH-funded |
| Lab location | 1 site (West Haven, United States) |
| Project start | August 15, 2026 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $496,520 |
| NIH project number | 1R15HL188996-01 |
| Project ID | NIH-11444679 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants would be patients who may receive nanoparticle-based therapies or whose blood samples could be studied to understand NP interactions (through collaboration with clinical centers).
✕Less likely to help
Patients not receiving nanoparticle-based therapies or whose blood samples are not part of related studies may not directly benefit.
What this research studies
If you or a loved one could benefit from smarter nanomedicine, this project will test how changing nanoparticle size, charge, and surface tweaks affect binding to blood cells and proteins in realistic flow conditions. Researchers will build a diverse library of lipid nanoparticles and measure how they interact with platelets, white and red blood cells, and plasma proteins. They will also create a computer model that predicts binding based on formulation, helping design safer, more effective therapies in the future.
Why it matters
Potential benefit: A predictive framework could guide the design of safer nanoparticles for patients needing targeted drug delivery.
How similar studies have gone: Previous work in nanoparticle–blood interactions has shown that formulation affects binding, and this project aims to create a validated predictive model—a promising but still emerging approach.
Where this research is happening
-
University of New Haven
West Haven, United States Active
Researchers
- Principal investigator: Amoako, Kagya a — University of New Haven
- Study coordinator: Amoako, Kagya a
Related research
Other NIH-funded projects on the same topics.
-
Role of a brain tumor RNA in glioblastoma where a unique lncRNA may drive cancer cells
A small, focused NIH grant explores how a brain cancer–related RNA called LINC01896 might control the growth of glioblastoma stem cells and influence treatment resistance.
-
Machine learning to map microbiome changes in ventilator-associated pneumonia
A machine-learning guided study will analyze 16S microbiome data from mechanically ventilated patients to help identify and diagnose ventillator-associated pneumonia earlier.
-
GSC-linked lncRNA GIHCG as a new therapeutic target in glioblastoma
Aims to understand and block a brain cancer RNA that helps glioblastoma stem cells grow, with the goal of improving survival for patients with glioblastoma.
-
Comparing in-person and telehealth visits for new mothers
This study looks at whether new moms and their babies do better with home visits from healthcare providers in person or through video calls, especially during the pandemic, to help improve future support for families.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.